-+ 0.00%
-+ 0.00%
-+ 0.00%

Halozyme Therapeutics President and CEO Helen Torley Reports Sale of $6 Million in Common Shares

PUBT·11/17/2026 01:34:57
Listen to the news
Halozyme Therapeutics President and CEO Helen Torley Reports Sale of $6 Million in Common Shares
  • Halozyme Therapeutics President and CEO Helen Torley sold 60,000 common shares Nov. 12-16, 2026.
  • Reported sale prices ranged from $96.848 to $101.72 per share.
  • Torley exercised options for 60,000 common shares at exercise prices of $16.65 and $18.41 per share during the same period.
  • Her direct common stock ownership remained unchanged at 767,780 shares following the transactions.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Halozyme Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001159036-26-000147), on November 16, 2026, and is solely responsible for the information contained therein.